PTCT
Price
$46.39
Change
-$1.47 (-3.07%)
Updated
Jul 22 closing price
Capitalization
3.68B
15 days until earnings call
SYRE
Price
$16.53
Change
+$0.18 (+1.10%)
Updated
Jul 22, 04:59 PM (EDT)
Capitalization
986.78M
8 days until earnings call
Interact to see
Advertisement

PTCT vs SYRE

Header iconPTCT vs SYRE Comparison
Open Charts PTCT vs SYREBanner chart's image
PTC Therapeutics
Price$46.39
Change-$1.47 (-3.07%)
Volume$1.11M
Capitalization3.68B
Spyre Therapeutics
Price$16.53
Change+$0.18 (+1.10%)
Volume$10.89K
Capitalization986.78M
PTCT vs SYRE Comparison Chart in %
Loading...
PTCT
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
SYRE
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
View a ticker or compare two or three
VS
PTCT vs. SYRE commentary
Jul 23, 2025

To compare these two companies we present long-term analysis, their fundamental ratings and make comparative short-term technical analysis which are presented below. The conclusion is PTCT is a Hold and SYRE is a Hold.

Interact to see
Advertisement
COMPARISON
Comparison
Jul 23, 2025
Stock price -- (PTCT: $47.86 vs. SYRE: $16.35)
Brand notoriety: PTCT and SYRE are both not notable
Both companies represent the Biotechnology industry
Current volume relative to the 65-day Moving Average: PTCT: 52% vs. SYRE: 93%
Market capitalization -- PTCT: $3.68B vs. SYRE: $986.78M
PTCT [@Biotechnology] is valued at $3.68B. SYRE’s [@Biotechnology] market capitalization is $986.78M. The market cap for tickers in the [@Biotechnology] industry ranges from $284.45B to $0. The average market capitalization across the [@Biotechnology] industry is $2.45B.

Long-Term Analysis

It is best to consider a long-term outlook for a ticker by using Fundamental Analysis (FA) ratings. The rating of 1 to 100, where 1 is best and 100 is worst, is divided into thirds. The first third (a green rating of 1-33) indicates that the ticker is undervalued; the second third (a grey number between 34 and 66) means that the ticker is valued fairly; and the last third (red number of 67 to 100) reflects that the ticker is undervalued. We use an FA Score to show how many ratings show the ticker to be undervalued (green) or overvalued (red).

PTCT’s FA Score shows that 1 FA rating(s) are green whileSYRE’s FA Score has 0 green FA rating(s).

  • PTCT’s FA Score: 1 green, 4 red.
  • SYRE’s FA Score: 0 green, 5 red.
According to our system of comparison, PTCT is a better buy in the long-term than SYRE.

Short-Term Analysis

It is best to consider a short-term outlook for a ticker by using Technical Analysis (TA) indicators. We use Odds of Success as the percentage of outcomes which confirm successful trade signals in the past.

If the Odds of Success (the likelihood of the continuation of a trend) for each indicator are greater than 50%, then the generated signal is confirmed. A green percentage from 90% to 51% indicates that the ticker is in a bullish trend. A red percentage from 90% - 51% indicates that the ticker is in a bearish trend. All grey percentages are below 50% and are considered not to confirm the trend signal.

PTCT’s TA Score shows that 3 TA indicator(s) are bullish while SYRE’s TA Score has 5 bullish TA indicator(s).

  • PTCT’s TA Score: 3 bullish, 6 bearish.
  • SYRE’s TA Score: 5 bullish, 4 bearish.
According to our system of comparison, SYRE is a better buy in the short-term than PTCT.

Price Growth

PTCT (@Biotechnology) experienced а -3.23% price change this week, while SYRE (@Biotechnology) price change was -0.37% for the same time period.

The average weekly price growth across all stocks in the @Biotechnology industry was +7.09%. For the same industry, the average monthly price growth was +19.23%, and the average quarterly price growth was +33.77%.

Reported Earning Dates

PTCT is expected to report earnings on Oct 23, 2025.

SYRE is expected to report earnings on Nov 06, 2025.

Industries' Descriptions

@Biotechnology (+7.09% weekly)

Biotechnology involves genetic or protein engineering to produce medicines/therapies for treating and preventing ailments. The industry also provides crucial ingredients for diagnostics. This multi-billion-dollar industry is heavily focused on research and development, as companies attempt to continually come up with cutting-edge solutions for health. New discoveries for the treatment of diseases provide opportunities for growth for a company in this industry. Discoveries, however, must pass the regulatory approval from the U.S. Food and Drug Administration (FDA) before they can make it to markets. Amgen Inc., Gilead Sciences, Inc. and Celgene Corporation are examples of companies in this industry.

SUMMARIES
Loading...
FUNDAMENTALS
Fundamentals
PTCT($3.68B) has a higher market cap than SYRE($987M). PTCT has higher P/E ratio than SYRE: PTCT (7.13) vs SYRE (1.72). PTCT YTD gains are higher at: 6.026 vs. SYRE (-29.768). PTCT has higher annual earnings (EBITDA): 839M vs. SYRE (-214.36M). PTCT has more cash in the bank: 2.03B vs. SYRE (565M). SYRE has less debt than PTCT: SYRE (0) vs PTCT (390M). PTCT has higher revenues than SYRE: PTCT (1.77B) vs SYRE (0).
PTCTSYREPTCT / SYRE
Capitalization3.68B987M373%
EBITDA839M-214.36M-391%
Gain YTD6.026-29.768-20%
P/E Ratio7.131.72415%
Revenue1.77B0-
Total Cash2.03B565M359%
Total Debt390M0-
FUNDAMENTALS RATINGS
PTCT vs SYRE: Fundamental Ratings
PTCT
SYRE
OUTLOOK RATING
1..100
566
VALUATION
overvalued / fair valued / undervalued
1..100
99
Overvalued
74
Overvalued
PROFIT vs RISK RATING
1..100
100100
SMR RATING
1..100
10098
PRICE GROWTH RATING
1..100
5360
P/E GROWTH RATING
1..100
2483
SEASONALITY SCORE
1..100
n/an/a

Tickeron ratings are formulated such that a rating of 1 designates the most successful stocks in a given industry, while a rating of 100 points to the least successful stocks for that industry.

SYRE's Valuation (74) in the Pharmaceuticals Major industry is in the same range as PTCT (99) in the Biotechnology industry. This means that SYRE’s stock grew similarly to PTCT’s over the last 12 months.

SYRE's Profit vs Risk Rating (100) in the Pharmaceuticals Major industry is in the same range as PTCT (100) in the Biotechnology industry. This means that SYRE’s stock grew similarly to PTCT’s over the last 12 months.

SYRE's SMR Rating (98) in the Pharmaceuticals Major industry is in the same range as PTCT (100) in the Biotechnology industry. This means that SYRE’s stock grew similarly to PTCT’s over the last 12 months.

PTCT's Price Growth Rating (53) in the Biotechnology industry is in the same range as SYRE (60) in the Pharmaceuticals Major industry. This means that PTCT’s stock grew similarly to SYRE’s over the last 12 months.

PTCT's P/E Growth Rating (24) in the Biotechnology industry is somewhat better than the same rating for SYRE (83) in the Pharmaceuticals Major industry. This means that PTCT’s stock grew somewhat faster than SYRE’s over the last 12 months.

TECHNICAL ANALYSIS
Technical Analysis
PTCTSYRE
RSI
ODDS (%)
N/A
Bearish Trend 7 days ago
90%
Stochastic
ODDS (%)
Bullish Trend 1 day ago
80%
Bearish Trend 1 day ago
90%
Momentum
ODDS (%)
Bearish Trend 1 day ago
89%
Bullish Trend 1 day ago
79%
MACD
ODDS (%)
Bearish Trend 1 day ago
81%
Bullish Trend 1 day ago
82%
TrendWeek
ODDS (%)
Bearish Trend 1 day ago
78%
Bullish Trend 1 day ago
84%
TrendMonth
ODDS (%)
Bearish Trend 1 day ago
75%
Bullish Trend 1 day ago
84%
Advances
ODDS (%)
Bullish Trend 6 days ago
75%
Bullish Trend 1 day ago
85%
Declines
ODDS (%)
Bearish Trend 15 days ago
81%
Bearish Trend 12 days ago
90%
BollingerBands
ODDS (%)
Bullish Trend 1 day ago
79%
Bearish Trend 1 day ago
90%
Aroon
ODDS (%)
Bearish Trend 1 day ago
67%
Bullish Trend 5 days ago
84%
View a ticker or compare two or three
Interact to see
Advertisement
PTCT
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
SYRE
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
Interesting Tickers
1D
1W
1M
1Q
6M
1Y
5Y
1 Day
MFs / NAMEPrice $Chg $Chg %
PCITX25.480.17
+0.67%
Victory Pioneer International Equ C
TROIX14.730.07
+0.48%
T. Rowe Price Overseas Stock I
BRSPX13.620.05
+0.37%
MFS Blended Research Small Cap Eq R1
SHXCX14.790.03
+0.20%
American Beacon Shapiro Equity Opps C
NDVBX16.31-0.05
-0.31%
MFS New Discovery Value B

SYRE and

Correlation & Price change

A.I.dvisor indicates that over the last year, SYRE has been loosely correlated with CGON. These tickers have moved in lockstep 59% of the time. This A.I.-generated data suggests there is some statistical probability that if SYRE jumps, then CGON could also see price increases.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To SYRE
1D Price
Change %
SYRE100%
+0.37%
CGON - SYRE
59%
Loosely correlated
+0.56%
IDYA - SYRE
59%
Loosely correlated
+1.02%
BEAM - SYRE
58%
Loosely correlated
+1.35%
XNCR - SYRE
56%
Loosely correlated
+1.45%
CRNX - SYRE
54%
Loosely correlated
-0.51%
More